HC Wainwright & Co. Maintains Buy on Axsome Therapeutics, Raises Price Target to $190
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has maintained a Buy rating on Axsome Therapeutics (NASDAQ:AXSM) and increased the price target from $180 to $190.
March 26, 2024 | 10:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Axsome Therapeutics' Buy rating is maintained by HC Wainwright & Co., with the price target raised from $180 to $190.
The increase in price target by a reputable analyst firm like HC Wainwright & Co. typically signals a strong confidence in the company's future performance. This can lead to increased investor interest and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100